MedTrace Logo

Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.

NCT00801437 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 457

Last updated 2021-02-18

No results posted yet for this study

Summary

This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma

Conditions

  • Glaucoma, Open-angle

Interventions

DRUG

Xalacom

Xalacom 1 drop into the affected eye daily

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Slovakia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00801437 on ClinicalTrials.gov